Clinical electrophysiology in the Netherlands: where do we stand?
作者信息
de Groot J R
机构信息
Heart Center, Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
出版信息
Neth Heart J. 2017 Oct;25(10):533-535. doi: 10.1007/s12471-017-1030-z. Epub 2017 Aug 2.
Abstract
摘要
相似文献
1
Clinical electrophysiology in the Netherlands: where do we stand?
Neth Heart J. 2017 Oct;25(10):533-535. doi: 10.1007/s12471-017-1030-z. Epub 2017 Aug 2.
2
Racism in health and health care in Europe: where does the Netherlands stand?
Eur J Public Health. 2007 Jun;17(3):240-1. doi: 10.1093/eurpub/ckm040.
3
The computer-based clinical record--where do we stand?
Ann Intern Med. 1993 Nov 15;119(10):1046-8. doi: 10.7326/0003-4819-119-10-199311150-00014.
4
[WILLEM EINTHOVEN (1860-1927)].
Klin Med (Mosk). 1963 Sep;41:154-6.
5
Twenty years of programmed stimulation of the heart: where to go from here?
Pacing Clin Electrophysiol. 1988 Jan;11(1):120-2. doi: 10.1111/j.1540-8159.1988.tb03937.x.
6
Centenary of tele-electrocardiography and telephonocardiography.
J Telemed Telecare. 2005;11(7):336-8. doi: 10.1258/135763305774472088.
7
Multidisciplinary heart failure programmes: where do we stand in the Netherlands?
Neth Heart J. 2005 Feb;13(2):45-46.
8
9
A review of physician-assisted suicide: where do you stand?
J Holist Nurs. 1996 Sep;14(3):206-22. doi: 10.1177/089801019601400304.
10
Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials?
J Am Coll Surg. 2002 Dec;195(6):855-64. doi: 10.1016/s1072-7515(02)01496-5.
本文引用的文献
1
Dutch outcome in implantable cardioverter-defibrillator therapy (DO-IT): registry design and baseline characteristics of a prospective observational cohort study to predict appropriate indication for implantable cardioverter-defibrillator.
Neth Heart J. 2017 Oct;25(10):574-580. doi: 10.1007/s12471-017-1016-x.
2
Trends in service time of pacemakers in the Netherlands: a long-term nationwide follow-up study.
Neth Heart J. 2017 Oct;25(10):581-591. doi: 10.1007/s12471-017-1024-x. Epub 2017 Aug 2.
3
A decade of atrial fibrillation ablation : Shifts in patient characteristics and procedural outcomes.
Neth Heart J. 2017 Oct;25(10):559-566. doi: 10.1007/s12471-017-1019-7.
4
Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry.
Neth Heart J. 2017 Oct;25(10):551-558. doi: 10.1007/s12471-017-1009-9.
5
Current practice of Dutch cardiologists in detecting and diagnosing atrial fibrillation: results of an online case vignette study.
Neth Heart J. 2017 Oct;25(10):567-573. doi: 10.1007/s12471-017-1010-3.
6
Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials.
Curr Med Res Opin. 2016 Jul;32(7):1277-9. doi: 10.1185/03007995.2016.1170672. Epub 2016 Apr 1.
7
Chronic performance of a leadless cardiac pacemaker: 1-year follow-up of the LEADLESS trial.
J Am Coll Cardiol. 2015 Apr 21;65(15):1497-504. doi: 10.1016/j.jacc.2015.02.022.
8
Permanent leadless cardiac pacing: results of the LEADLESS trial.
Circulation. 2014 Apr 8;129(14):1466-71. doi: 10.1161/CIRCULATIONAHA.113.006987. Epub 2014 Mar 24.
9
FOLLOWPACE study: a prospective study on the cost-effectiveness of routine follow-up visits in patients with a pacemaker.
Europace. 2006 Jan;8(1):60-4. doi: 10.1093/europace/euj005.
10
The role of premature beats in the initiation and the termination of supraventricular tachycardia in the Wolff-Parkinson-White syndrome.
Circulation. 1967 Nov;36(5):644-62. doi: 10.1161/01.cir.36.5.644.
Zotero 插件